Andrew Tsai
Stock Analyst at Jefferies
(0.54)
# 3,980
Out of 4,918 analysts
23
Total ratings
25%
Success rate
-27.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Buy | $40 → $35 | $15.91 | +119.99% | 3 | Jul 24, 2025 | |
| STOK Stoke Therapeutics | Initiates: Buy | $30 | $12.91 | +132.38% | 1 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Buy | $70 | $47.37 | +47.77% | 1 | Jul 14, 2025 | |
| VRNA Verona Pharma | Maintains: Buy | $95 → $110 | $105.18 | +4.58% | 1 | Jun 11, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Hold | $29 → $2.5 | $2.99 | -16.39% | 2 | May 28, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $200 | $103.02 | +94.14% | 1 | Apr 7, 2025 | |
| BEKE KE Holdings | Maintains: Overweight | $19 → $27 | $18.20 | +48.35% | 2 | Mar 19, 2025 | |
| RLMD Relmada Therapeutics | Upgrades: Buy | $3.5 → $13 | $0.59 | +2,102.64% | 2 | Sep 17, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $35 | $14.15 | +147.35% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $33 | $3.05 | +981.97% | 1 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $0.2 → $15 | $2.92 | +413.70% | 2 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $1.07 | +180.37% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $3 | $0.37 | +710.37% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $8.05 | +148.45% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $4.17 | +547.48% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $30.48 | -24.54% | 1 | Jun 1, 2020 |
Sarepta Therapeutics
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $15.91
Upside: +119.99%
Stoke Therapeutics
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $12.91
Upside: +132.38%
BridgeBio Pharma
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $47.37
Upside: +47.77%
Verona Pharma
Jun 11, 2025
Maintains: Buy
Price Target: $95 → $110
Current: $105.18
Upside: +4.58%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $2.99
Upside: -16.39%
Axsome Therapeutics
Apr 7, 2025
Initiates: Buy
Price Target: $200
Current: $103.02
Upside: +94.14%
KE Holdings
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $18.20
Upside: +48.35%
Relmada Therapeutics
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $0.59
Upside: +2,102.64%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $14.15
Upside: +147.35%
Alto Neuroscience
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $3.05
Upside: +981.97%
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $2.92
Upside: +413.70%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.07
Upside: +180.37%
Jun 23, 2022
Downgrades: Hold
Price Target: $32 → $3
Current: $0.37
Upside: +710.37%
Feb 1, 2022
Initiates: Buy
Price Target: $20
Current: $8.05
Upside: +148.45%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $4.17
Upside: +547.48%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $30.48
Upside: -24.54%